PTX 2.56% 3.8¢ prescient therapeutics limited

Ann: Canadian Patent Granted for PTX-200, page-13

  1. 87 Posts.
    lightbulb Created with Sketch. 13

    PTX is fully-funded to fast-track development on key projects. Recently completed capital raising amounted to $9.1 Million.
    US based H.C. WAINWRIGHT & CO. EQUITY RESEARCH initiateda coverage recently with a Buy rating and $A0.20 price target.
    Expecting numerous catalyst/news flow in the near term.


    https://hotcopper.com.au/data/attachments/1554/1554658-aaa28689a90d8856533f82c18119f95a.jpg

    Credit Suisse took position at a buy price of 0.05 cents on1-9 April 2019.

    https://hotcopper.com.au/data/attachments/1554/1554662-69bd8f51690d06ac74d7ba32254e39f9.jpg


    Regal Funds & Australian Ethical Investments are majorshareholders.

    https://hotcopper.com.au/data/attachments/1554/1554659-eecf4897f44c886f62b67413bdc069a9.jpg


 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
-0.001(2.56%)
Mkt cap ! $30.60M
Open High Low Value Volume
3.9¢ 3.9¢ 3.8¢ $47.91K 1.256M

Buyers (Bids)

No. Vol. Price($)
11 881755 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 150000 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.